Clinical trials: Attention Disorder With Hyperactivity (ADHD)
Cognitive Function, Quality of Life
EFFECT OF PERCEPTUAL-MOTOR TRAINING ON COGNITIVE FUNCTIONS, MOTOR ABILITIES AND QUALITY OF LIFE IN CHILDREN WITH ATTENTION DEFICIT HYPERACTIVE DISORDER
This study aims to Determine the effect of perceptual-motor training on: cognitive functions, motor abilities, and quality of life in ADHD children.
- Conditions
- Cognitive Function, Quality of Life, ADHD - Attention Deficit Disorder With Hyperactivity, Motor Abilities
- Trial name
- NCT07139210
- Testing
- perceptual motor training
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Cairo University
Neurodevelopmental Disorders, Attention Deficit Hyperactivity Disorder
Validity of Neurocognitive Assessment Methods in Childhood ADHD
The aim of the study is to examine the prospective validity of neurocognitive functions and emotional factors in schoolchildren with ADHD and a control group of typically developing schoolchildren at baseline and after three…
- Trial name
- NCT04201509
- Where
- Sweden
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Region Skane
Attention Deficit Disorder
Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attention-deficit/Hyperactivity
A study to evaluate the long term maintenance of efficacy of using Guanfacine Hydrochloride (SPD-503) for the treatment of ADHD in Children aged 6-17 years in Europe, Australia, Canada and the US.
- Trial name
- SPD503-315 (NCT03662763)
- Testing
- Extended-release Guanfacine Hydrochloride (SPD503)
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Maastricht University Medical Center
Neurocognitive Impairment, Acute Lymphoblastic Leukemia
Risk of Psychopathology and Neurocognitive Impairment in Leukemia Survivors
1. This study will evaluate the association between changes in basic cognitive and behavioral functioning by the end of chemotherapy treatment, and the later development of higher order executive functions in pediatric acute…
- Trial name
- NCT01014195
- Testing
- Neurocognitive and behavioral evaluation
- Where
- United States
- Volunteers
- 237 people
- Sponsor
- St. Jude Children's Research Hospital
Neurodevelopmental Disorders, Autism Spectrum Disorder (ASD)
Single Session Support for Parents of Children With Neurodevelopmental Disabilities Struggling With Anxious Avoidance
This study will inform the development of a brief online program to help parents better understand and respond to anxiety-related behaviors in children with neurodevelopmental disorders (NDDs) such as autism spectrum disorder…
- Conditions
- Neurodevelopmental Disorders, Autism Spectrum Disorder (ASD), Attention-Deficit/Hyperactivity Disorder (ADHD), Intellectual Disability
- Trial name
- EMPOWER-ND (NCT07898592)
- Testing
- EMPOWER-ND
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Boston University Charles River Campus
COVID-19, Cognitive Impairment
Computerized Training of Attention and Working Memory in Post COVID-19 Patients With Cognitive Complaints
Many post COVID-19 patients suffer from cognitive deficits, even after 1 year after hospitalization. These complaints have a huge impact on psychological well-being and quality of life.
- Conditions
- COVID-19, Cognitive Impairment, Cognition Disorder, Memory Disorders
- Trial name
- CO-TRAINER (NCT05831839)
- Testing
- RehaCom
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Erasmus Medical Center
Attention Deficit Hyperactivity Disorder
Organizational Skills Interventions for Children With Attention Deficit Hyperactivity Disorder (ADHD)
Attention-Deficit/Hyperactivity Disorder (ADHD) is one of the most commonly diagnosed childhood disorders, with prevalence rates estimated at 8% (Froehlich et al. 2007).
- Trial name
- NCT01176136
- Testing
- Homework, Organization, and Planning Skills (HOPS) Intervention
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
ADHD
Prevalence of Attention Deficit/Hyperactivity Disorder and Parenting Stress in School-age Children in Chongqing, China
Attention deficit hyperactivity disorder (ADHD) is a common chronic neurodevelopmental disorder. Around 7.2% of children around the world are suffering from ADHD, while a chinese meta-analysis shows that the prevalence is 6.28%.
- Trial name
- PADHDPS (NCT05231902)
- Where
- China
- Volunteers
- 6,480 people, healthy volunteers welcome
- Sponsor
- Chen Li
Attention Deficit Hyperactivity Disorder
Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHD
The purpose of this study is to assess changes in ADHD symptoms and tolerability of medication in children and adolescents switching from a stimulant to atomoxetine.
- Trial name
- NCT00485875
- Testing
- Atomoxetine Hydrochloride
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Neuroendocrine Substrates, Candidate Genes and Endophenotypes in ADHD
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common child and adolescent psychiatric disorders. In recent years, some researchers have become interested in analyzing neuroendocrine substrate levels in ADHD…
- Trial name
- NCT02392169
- Testing
- Methylphenidate
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- Chang Gung Memorial Hospital
Irritable Mood, ADHD
Irritability in Children With ADHD and Emotion Dysregulation
Objective: Emotion dysregulation is common among children with ADHD and associated with a broad range of adult psychopathology, which is similar to the longitudinal outcomes of childhood irritability.
- Trial name
- NCT05974241
- Testing
- Methylphenidate, aripiprazole, and combination
- Where
- Taiwan
- Volunteers
- 36 people
- Sponsor
- Tri-Service General Hospital (TSGH)
Attention Deficit Hyperactivity Disorder
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting
This Phase 3 pivotal efficacy trial will examine the effects of HLD200 (methylphenidate) in patients aged 6-12 years with ADHD in a naturalistic setting.
- Trial name
- NCT02520388
- Testing
- HLD200 methylphenidate hydrochloride (MPH) Capsules
- Where
- 21 sites in United States
- Volunteers
- 163 people
- Sponsor
- Ironshore Pharmaceuticals and Development, Inc
Attention Deficit Hyperactivity Disorder
Expectation of Driving Performance in Young Adults With ADHD Assessed by Driving Simulator and Seat Pressure Mapping
Adolescents suffering of ADHD may have impaired driving performance. The investigators would like to check the differences in driving performance in young adults(aged: 15-18 years) with ADHD by driving simulator and seat pressure…
- Trial name
- NCT01179386
- Where
- Israel
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Meir Medical Center
ADHD
Multimodal Brain Imaging of Methylphenidate in Children and Adolescents With ADHD
The goal of this proposal is to develop brain imaging tools to measure the effects of methylphenidate in children and adolescents with attention deficit hyperactivity disorder (ADHD).
- Trial name
- NCT06077669
- Testing
- Methylphenidate
- Where
- United States
- Sponsor
- Johns Hopkins University
Attention-Deficit, Hyperactivity Disorder
Diagnostic Accuracy and Safety of the Attention-Deficit/Hyperactivity Disorder Auxiliary Evaluation System (AHEF) in Chinese Children Aged 6 to 12
This clinical trial aims to evaluate the diagnostic efficacy and safety of the Attention Deficit Hyperactivity Disorder Assessment System (AHEF) in children aged 6 to 12 in China, while ensuring the safety of the subjects and…
- Trial name
- NCT07683156
- Testing
- AHEF
- Where
- 8 sites in China
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Chongqing Jinsaixing Medical Technology Co., Ltd
Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder
Brain Imaging in Babies Study
The aims of the BIBS Study The Brain Imaging in Babies study (BIBS) aims to improve understanding of how a baby's brain develops from before birth, up until 3-4 years of age.
- Conditions
- Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder, Neurodevelopmental Conditions, COVID-19
- Trial name
- BIBS (NCT04443179)
- Where
- United Kingdom
- Volunteers
- 790 people, healthy volunteers welcome
- Sponsor
- King's College London
Attention Deficit Hyperactivity Disorder (ADHD)
Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder
The purpose of this study is to evaluate the long-term safety of SPD489 administered as a daily morning dose (5, 10, 15, 20, and 30 mg/day) in preschool children diagnosed with Attention-deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT02466386
- Testing
- SPD489
- Where
- 50 sites in United States
- Volunteers
- 113 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder (ADHD)
Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe
For subjects in Europe that have already participated in either Study SPD503-315 or SPD503-316. This is an extension study that will allow participants access to Extended-release Guanfacine Hydrochloride (HCl) for up to 2 years.
- Trial name
- NCT01500694
- Testing
- Extended-release Guanfacine HCl (Intuniv, SPD503)
- Where
- 60 sites in Austria, Belgium and 11 more
- Volunteers
- 215 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder (ADHD), Substance-related Disorder
Deficit Hyperactivity Disorder / Substance Use Disorder Comorbidity in Integrated Treatment
Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorders (SUDs) is a highly common comorbid condition associated with serious medical and psychosocial consequences.
- Trial name
- ATTenTIFF (NCT06858527)
- Testing
- TAU+integrated group CBT
- Where
- France
- Volunteers
- 132 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
ADHD
PRC-063 in Adolescent ADHD
The purpose of this randomized, placebo-controlled, double-blind, parallel group study is to evaluate the clinical efficacy and safety of PRC-063 in adolescents with ADHD.
- Trial name
- NCT02139111
- Testing
- PRC-063 25 mg, PRC-063 45 mg, PRC-063 70 mg
- Where
- 43 sites in United States, Canada
- Volunteers
- 360 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.